Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10400338 | 0.86 | SMN1; SMN2 (0.51) | SMN1; SMN2TDP1ALDH1A1HRH2PRMT6 | |
| SCHEMBL8562745 | 0.81 | HRH2 (0.56) | SMN1; SMN2TDP1ALDH1A1HRH2 | |
| SCHEMBL13293711 | 0.81 | ALDH1A1 (0.61) | SMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL9735417 | 0.79 | KDM4E (0.57) | SMN1; SMN2ALDH1A1HRH2PRMT6 | |
| SCHEMBL3912738 | 0.79 | DRD2 (0.58) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL5167259 | 0.78 | HRH2 (0.59) | SMN1; SMN2ALDH1A1HRH2PRMT6 | |
| SCHEMBL10682807 | 0.78 | KDM4E (0.63) | SMN1; SMN2ALDH1A1HRH2 | |
| SCHEMBL10934478 | 0.78 | HRH2 (0.59) | HRH2 | |
| SCHEMBL13544385 | 0.78 | HRH3 (0.74) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL13293747 | 0.78 | HRH3 (0.59) | SMN1; SMN2ALDH1A1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0159012-B1 | SULFONAMIDINES, A PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FERRER INTERNACIONAL, S.A. (ES) | 1989-02-01 | — | — | EP | claimed |